We chose CXC chemokine receptor 4 (CXCR4) as our drug target because its expression has been observed in multiple types of cancers, including breast, lung, and prostate cancers[47–51]; moreover, there are extensive discussions in the literature regarding active/inactive molecules against the CXCR4[52–54]. Here, CXCR4 is linked to prostate carcinoma.